AUSTRAL Dx Secures €2.5M Seed Round to Revolutionize Lung & Cardiac Imaging with Airborne Ultrasound Technology

We are thrilled to announce that AUSTRAL Dx, a trailblazing French start-up, has successfully raised €2,500,000 in its latest funding round. This significant financial milestone will enable the company to accelerate the development of its groundbreaking imaging technology, which employs airborne ultrasounds to capture and map internal vibrations with unmatched precision. AUSTRAL Dx’s innovative device is designed to detect vibrations originating from the lungs—either directly or via vocal fremitus—as well as those from the heartbeat, all mapped on the skin’s surface with an accuracy of up to 1 micron. This level of precision positions the device at the forefront of diagnostic medical equipment, promising to revolutionize the way lung and cardiac diseases are diagnosed and monitored. By harnessing the power of advanced imaging, AUSTRAL Dx aims to offer clinicians a more detailed and dynamic view of patient physiology, thereby improving early diagnosis and follow-up care. The recently raised funds will support critical research and development initiatives, allowing the company to refine its technology further, scale production, and prepare for broader market integration. As the healthcare landscape becomes increasingly focused on precision medicine, this investment marks a pivotal moment not only for the company but also for the future of non-invasive medical imaging. With this new financial backing, AUSTRAL Dx is well-positioned to bridge the gap between cutting-edge technology and practical clinical application, ultimately improving patient outcomes and setting new standards in the diagnosis and management of pulmonary and cardiac conditions.